• Home slider image
Cerus Forms Group to Research Optimal Production
 of COVID-19 Convalescent Plasma.
Read the press release

Cerus Corporation (Nasdaq: CERS) announced today that it has formed a collaborative research group with the aim of optimizing convalescent plasma therapy for COVID-19 patients. The research group seeks to define the key characteristics that influence the efficacy of convalescent plasma, including the level and nature of anti-COVID-19 antibodies, optimal collection timing, dosing and how these influence responses to the therapy regimen. Cerus’ research group collaborators include the California Department of Public Health, the University of California, Irvine’s Vaccine Development Research Laboratory, the Vitalant Research Institute, the California National Primate Research Center, and Enable Biosciences. Read the press release >

We are focused on ensuring the safety of our team 

and our stakeholders as we endeavor to achieve our mission
 establishing INTERCEPT as the global standard of care


In the face of the current COVID-19 pandemic, we have implemented actions to:

>  Ensure the safety of our employees and their families

 Sustain continuity of our supply chain to support current and anticipated demand

    for our products

>  Engage with regulatory authorities, blood centers, and national transfusion

    services to expand availability of the platelet supply

>  Study the efficacy of INTERCEPT against SARS-CoV-2

>  Support blood centers evaluating the use of Convalescent Plasma

Learn more >

At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.

Our Mission & Core Values

Cerus will establish INTERCEPT as the standard of care for transfused blood components globally and enable our customers to do everything in their power to deliver safe and effective blood products to patients.

  • The patient is our ultimate concern. We intend to make INTERCEPT the standard of care for blood safety globally.
  • We will be a dependable partner for all blood services to allow them to achieve their important mission, concentrating on ensuring the quality, supply, and operational efficiency of our products. No other company will know blood center operations better, nor provide better service.
  • We operate as one team and resolve to attract and retain the best people in the business. We operate in multiple cultures and geographies and work in a coordinated, mutually supportive fashion.
  • Integrity, perseverance, scientific rigor, and urgency are core to who we are.
Cerus homepage image

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600